Chimeric, an Australian biotechnology company, has acquired the exclusive worldwide rights to develop and commercialize certain patents related to City of Hope's CLTX-CAR T cells, as well as further develop the therapy for other cancers.

Uniquely, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and is engineered to serve as the CAR recognition domain. The CLTX CAR T-cell therapy was developed and tested by City of Hope researchers. In early studies, the team found that CLTX-CAR T cells recognized and killed broad populations of glioblastoma cells while ignoring nontumor cells in the brain and other organs. The therapy is currently being evaluated in a phase I clinical trial to treat glioblastoma.

Clinical test allows patients to be directly matched to clinical trial
Ashion Analytics has partnered with Elevation Oncology to match patients harboring an NRG1 gene fusion identified with Ashion's Gem Extra test with a...

City of Hope sponsors COVID-19 research
City of Hope released details of multiple COVID-19 research projects, including the development of two potential vaccines, new therapies, and better screening...